INSM News - Candlesense

Insmed To Present at September Investor Conferences

BRIDGEWATER, N.J., Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transf...

Investor

17 days ago

Read more prnewswire

Amber Specialty Pharmacy Begins Dispensing Newly Approved BRINSUPRI™ (brensocatib) for Non-Cystic Fibrosisbronchiectasis (NCFB)

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing BRINSUPRI™ (brensocatib) following the medicatio...

What regulatory or payer hurdles remain that could affect the drug’s commercial rollout? How might the approval influence future pipeline developments or partnership opportunities for Insmed? Are there any supply chain or manufacturing constraints that could impact product availability?

Drug approval

25 days ago

VytlOne Announces New Partnership with Insmed

AMARILLO, Texas, Aug. 13, 2025 /PRNewswire/ -- Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl pep...

What is the timeline for rollout and sales ramp-up for Brinsupri through this partnership? What regulatory or reimbursement risks are associated with the distribution of Brinsupri? How might this news influence the stock price of INSM and VytlOne?

Partnership

25 days ago

Read more prnewswire

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced that it was selected by Insme...

How does this partnership align with Insmed's long‑term growth strategy and pipeline development? Will the partnership impact the pricing strategy or reimbursement negotiations for BRINSUPRI™? What is the anticipated effect of this news on INSM stock price in the short and medium term?

Partnership

25 days ago

Read more prnewswire

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in P...

What are the expectations for future growth drivers beyond ARIKAYCE® (e.g., new indications, geographic expansion, or pipeline assets) that could affect long‑term valuation? What are the underlying assumptions for any forward‑looking guidance, and are there any red‑flag risk factors noted in the full SEC filing? How might the earnings beat and guidance affect the company's short‑term technical momentum and options implied volatility?

Earnings

about 1 month ago

Read more prnewswire